Cargando…

Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)

INTRODUCTION: Phospholipids are altered in brains of patients with dementia and some studies suggest their plasma levels may be useful in the detection of mild cognitive impairment (MCI) and dementia. METHODS: We measured 188 plasma metabolites in participants who underwent a detailed neuropsycholog...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Danni, Misialek, Jeffrey R., Boerwinkle, Eric, Gottesman, Rebecca F., Sharrett, A. Richey, Mosley, Thomas H., Coresh, Josef, Wruck, Lisa M., Knopman, David S., Alonso, Alvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925799/
https://www.ncbi.nlm.nih.gov/pubmed/27408938
http://dx.doi.org/10.1016/j.dadm.2016.02.008
Descripción
Sumario:INTRODUCTION: Phospholipids are altered in brains of patients with dementia and some studies suggest their plasma levels may be useful in the detection of mild cognitive impairment (MCI) and dementia. METHODS: We measured 188 plasma metabolites in participants who underwent a detailed neuropsychological assessment and classified as normal (n = 153), MCI (n = 145), or dementia (n = 143) by expert adjudication. RESULTS: Among 10 phospholipids recently implicated as altered in dementia, higher concentration of PC aa C36:6 was significantly associated with decreased prevalence of dementia (odds ratio = 0.71, 95% confidence interval = 0.50–1.00 per 1−SD increase). Adding these phospholipids to a model including multiple predictors of dementia led to only minimal improvement in detection (C statistic changed from 0.702 to 0.71). DISCUSSION: Some phospholipids and metabolites were altered in MCI and dementia but cross-sectional association was relatively weak and did not improve detection of MCI and dementia beyond information provided by clinical variables.